Literature DB >> 26652608

Weighing the evidence for harm from long-term treatment with antipsychotic medications: A systematic review.

Nancy Sohler1, Ben G Adams2, David M Barnes2, Gregory H Cohen2, Seth J Prins2, Sharon Schwartz2.   

Abstract

Research findings supporting the use of antipsychotic medication for acute treatment of schizophrenia are relatively consistent and undisputed. However, the rationale for recommending long-term antipsychotic medication treatment-the current standard of care treatment strategy-is unclear. A controversial hypothesis proposed recently suggests people with schizophrenia who are exposed to long-term treatment with antipsychotic medications have worse outcomes than people with schizophrenia who are not exposed to these medications. We tested whether a systematic appraisal of published literature would produce data consistent with this hypothesis. We reviewed the published literature to identify studies of patients with psychotic disorders who were followed for at least 2 years that compared outcomes in patients who received antipsychotic medication during the follow-up with patients who did not receive antipsychotic medication during the follow-up. We included all English language articles published through 2013 in this review. Our process for selecting studies and documenting study findings included a consensus decision of 2 members of the research team. We found the published data to be inadequate to test this hypothesis. By extension, these data were also inadequate to conclusively evaluate whether long-term antipsychotic medication treatment results in better outcomes on average. We conclude that careful reappraisal of existing data is useful to ensure standard of care treatment strategies are indeed evidence-based. In the case of long-term use of antipsychotic medications, new data may be needed to establish a sufficient evidence base to understand its benefit/risk balance for patients with schizophrenia. (PsycINFO Database Record (c) 2016 APA, all rights reserved).

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26652608      PMCID: PMC4907881          DOI: 10.1037/ort0000106

Source DB:  PubMed          Journal:  Am J Orthopsychiatry        ISSN: 0002-9432


  37 in total

Review 1.  Ethics and early intervention in psychosis: keeping up the pace and staying in step.

Authors:  P D McGorry; A Yung; L Phillips
Journal:  Schizophr Res       Date:  2001-08-01       Impact factor: 4.939

2.  Drug-free research in schizophrenia: an overview of the controversy.

Authors:  Paul S Appelbaum
Journal:  IRB       Date:  1996 Jan-Feb

3.  Comparison of two five-year follow-up studies: 1948 to 1952 and 1967 to 1972.

Authors:  J S Bockoven; H C Solomon
Journal:  Am J Psychiatry       Date:  1975-08       Impact factor: 18.112

4.  Antipsychotic medication during the critical period following remission from first-episode psychosis: less is more.

Authors:  Patrick McGorry; Mario Alvarez-Jimenez; Eoin Killackey
Journal:  JAMA Psychiatry       Date:  2013-09       Impact factor: 21.596

Review 5.  Does long-term treatment of schizophrenia with antipsychotic medications facilitate recovery?

Authors:  Martin Harrow; Thomas H Jobe
Journal:  Schizophr Bull       Date:  2013-03-19       Impact factor: 9.306

6.  Metabolic changes associated with antipsychotic use.

Authors:  Joseph A Lieberman
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2004

7.  Drug and sociotherapy in the aftercare of schizophrenic patients. II. Two-year relapse rates.

Authors:  G E Hogarty; S C Goldberg; N R Schooler; R F Ulrich
Journal:  Arch Gen Psychiatry       Date:  1974-11

8.  Neuroleptic withdrawal in schizophrenic patients. A review of the literature.

Authors:  P L Gilbert; M J Harris; L A McAdams; D V Jeste
Journal:  Arch Gen Psychiatry       Date:  1995-03

9.  Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial.

Authors:  Lex Wunderink; Roeline M Nieboer; Durk Wiersma; Sjoerd Sytema; Fokko J Nienhuis
Journal:  JAMA Psychiatry       Date:  2013-09       Impact factor: 21.596

10.  Are there schizophrenics for whom drugs may be unnecessary or contraindicated?

Authors:  M Rappaport; H K Hopkins; K Hall; T Belleza; J Silverman
Journal:  Int Pharmacopsychiatry       Date:  1978
View more
  4 in total

1.  An observational study of antipsychotic medication discontinuation in first-episode psychosis: clinical and functional outcomes.

Authors:  Ashok Malla; Srividya N Iyer; Ridha Joober; Thara Rangaswamy; Padmavati Ramachandran; Norbert Schmitz; Aarati Taksal; Greeshma Mohan; Howard C Margolese
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2022-01-18       Impact factor: 4.328

2.  The debate regarding maintenance treatment with antipsychotic drugs in schizophrenia.

Authors:  Michael Davidson
Journal:  Dialogues Clin Neurosci       Date:  2018-09       Impact factor: 5.986

3.  Psychotherapy in Psychosis: Experiences of Fully Recovered Service Users.

Authors:  Jone Bjornestad; Marius Veseth; Larry Davidson; Inge Joa; Jan Olav Johannessen; Tor Ketil Larsen; Ingrid Melle; Wenche Ten Velden Hegelstad
Journal:  Front Psychol       Date:  2018-09-04

4.  Why Service Users Choose Medication-Free Psychiatric Treatment: A Mixed-Method Study of User Accounts.

Authors:  Kari Standal; Ole Andre Solbakken; Jorun Rugkåsa; Astrid Ringen Martinsen; Margrethe Seeger Halvorsen; Allan Abbass; Kristin Sverdvik Heiervang
Journal:  Patient Prefer Adherence       Date:  2021-07-23       Impact factor: 2.711

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.